Abstract: This invention provides a DNA vaccine which comprises a naked DNA incorporating and expressing in vivo a nucleotide sequence encoding an antigenic polypeptide, preferably a gene of a pathogenic agent, and at least one adjuvant compound chosen from the polymers of acrylic or methacrylic acid and copolymers of maleic anhydride and alkenyl derivative. The adjuvant compound is preferably a carbomer or an EMA®. This invention also provides a method of enhancing a DNA vaccine and/or the immunogenicity of a DNA vaccine.

Abstract: DNA vaccine against a pathogen affecting farm animals, in particular bovines or porcines, comprising a plasmid containing a nucleotide sequence encoding an immunogen of a pathogen of the animal species considered, under conditions allowing the in vivo expression of this sequence, and a cationic lipid containing a quaternary ammonium salt, of formula in which R1 is a saturated or unsaturated linear aliphatic radical having 12 to 18 carbon atoms, R2 is another aliphatic radical containing 2 or 3 carbon atoms, and X a hydroxyl or amine group, this lipid being preferably DMRIE.

Abstract: The invention relates to the sequence of the capsid gene and a corresponding cDNA sequence, of a dominant FCV strain called FCV 431. It also relates to the sequence of the capsid gene as well as the cDNA sequence of a complementary strain called G1. The cDNA sequences may be incorporated into expression vectors for the preparation of immunogenic preparations and of recombinant or subunit vaccines allowing vaccination against feline calicivirosis.

Abstract: Improved vaccines or immunogenic or immunological compositions, and methods for making and using the same.

Abstract: Disclosed and claimed are immunogenic compositions to induce an immune response against West Nile (WN) virus, recombinants, for instance recombinant avipox viruses containing and expressing exogenous polynucleotide(s) from WN virus, and methods for making and using the same.

Abstract: The recombinant live vaccine comprises a viral vector incorporating and expressing in vivo a heterologous nucleotide sequence, preferably a gene of a pathogenic agent, and at least one adjuvant compound chosen from the acrylic or methacrylic polymers and the copolymers of maleic anhydride and an alkenyl derivative. It is in particular a polymer of acrylic or methacrylic acid cross-linked with a polyalkenyl ether of a sugar or polyalcohol (carbomer), in particular cross-linked with an allyl sucrose or with allylpentaerythritol. It may also be a copolymer of maleic anhydride and ethylene cross-linked, for example, with divinyl ether.

Abstract: An immunogenic or vaccine composition to induce an immune response or protective immune response against West Nile virus (WNV) in an animal susceptible to WNV. The composition includes a pharmaceutically or veterinarily acceptable vehicle or excipient, and a vector. The vector contains heterologous nucleic acid molecule(s), expresses in vivo in the animal WNV antigen, immunogen or epitope thereof, e.g., WNV E; WNV prM and E; WNV M and E; WNV prM, WNV M and E, WNV polyprotein prM-E, WNV polyprotein M-E, or WNV polyprotein prM-M-E. The composition can contain an adjuvant, such as carbomer. Methods for making and using such a composition, including prime-boost regimes and including as to differential diagnosis, are also contemplated.

Abstract: Disclosed and claimed are methods and compositions and kits for the vaccination or immunization of an animal, such as a mammal, advantageously a bovine, involving a prime-boost regimen.

Abstract: A vaccine against foot-and-mouth disease, using as antigen an efficient amount of empty capsids of the foot-and-mouth virus. The empty capsids are obtained by expressing, in eukaryotic cells, cDNA of the P1 region of the foot-and-mouth virus genome coding for the capsid and cDNA of the region of the foot-and-mouth virus genome coding for protease 3C. The vaccine further includes a carrier or excipient pharmaceutically acceptable in veterinary medicine.

Abstract: The invention relates to the sequence of the capsid gene and a corresponding cDNA sequence, of a dominant FCV strain called FCV 431. It also relates to the sequence of the capsid gene as well as the cDNA sequence of a complementary strain called G1. The cDNA sequences may be incorporated into expression vectors for the preparation of immunogenic preparations and of recombinant or subunit vaccines allowing vaccination against feline calicivirosis.

Abstract: Disclosed and claimed are immunogenic compositions to induce an immune response against West Nile (WN) virus, recombinants, for instance recombinant avipox viruses containing and expressing exogenous polynucleotide(s) from WN virus, and methods for making and using the same.

Abstract: Improved vaccines or immunogenic or immunological compositions, and methods for making and using the same.

Abstract: The invention relates to the sequence of the capsid gene and a corresponding cDNA sequence, of a dominant FCV strain called FCV 431. It also relates to the sequence of the capsid gene as well as the cDNA sequence of a complementary strain called G1. The cDNA sequences may be incorporated into expression vectors for the preparation of immunogenic preparations and of recombinant or subunit vaccines allowing vaccination against feline calicivirosis.

Abstract: Porcine circovirus-2 (PCV-2) is a recently identified agent wherein the potential spectrum of PCV-2-associated disease has been expanded by evidence of vertical and sexual transmission and associated reproductive failure in swine populations. PCV-2 was isolated from a litter of aborted piglets from a farm experiencing late term abortions and stillbirths. Severe, diffuse myocarditis was present in one piglet associated with extensive immunohistochemical staining for PCV-2 antigen. Variable amounts of PCV-2 antigen were also present in liver, lung and kidney of multiple fetuses.

Abstract: The invention relates to antigenic preparations and vaccines directed against the porcine multisystemic wasting syndrome (PMWS), comprising at least one porcine circovirus antigen, preferably type II, and at least one porcine parvovirus antigen.

Abstract: DNA vaccine against a pathogen affecting farm animals, in particular bovines or porcines, comprising a plasmid containing a nucleotide sequence encoding an immunogen of a pathogen of the animal species considered, under conditions allowing the in vivo expression of this sequence, and a cationic lipid containing a quaternary ammonium salt, of formula 1

Abstract: The recombinant live vaccine comprises, as vector, a feline herpesvirus comprising and expressing at least one nucleotide sequence encoding a polypeptide, this sequence being inserted into the ORF5 and/or ORF2 sites. Polyvalent vaccine formula and feline herpesvirus DNA fragments.

Abstract: The invention comprises the nucleotide sequences comprising the FIPV S gene, or a fragment of this gene, which are modified in at least one of the antigenic regions A1 and A2 which are involved in enhancement, as well as the use of these sequences for the expression of modified proteins, and for the construction of recombinant viruses or expression plasmids, and the use of the recombinant viruses as vaccines against feline infectious peritonitis, the use of the expression plasmids as immunizing composition by direct injection of the said plasmids into cats, and the use of the modified proteins as vaccine.

Abstract: A recombinant virus is provided which is obtained from a BHV virus originally having the gI gene whose DNA sequence is delimited by nucleotides 172 and 1311 of SEQ ID NO:1 herein and which has been mutated by total or partial deletion and/or insertion in this region. By the mutation in this region, there is no longer any expression of the glycoprotein which has been mutated or rendered inactive, and thus animals vaccinated with these mutants do not develop antibodies against the glycoprotein and can be serologically distinguished from animals infected by field BHV-1 strains and other vaccinal strains currently used. A method of using the present recombinant virus is also provided which allows one to distinguish infected animals from vaccinated animals in a manner that has not previously been possible using presently available commercial vaccines.

Abstract: The recombinant live vaccine comprises, as vector, a feline herpesvirus comprising and expressing at least one nucleotide sequence encoding a polypeptide, this sequence being inserted into the ORF5 and/or ORF2 sites. Polyvalent vaccine formula and feline herpesvirus DNA fragments.